5.01
-0.13
(-2.53%)
Real-time:
2:52PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 4.98 - 5.29 |
| 52 week | 3.20 - 7.08 |
| Open | 5.14 |
| Vol / Avg. | 86,797.00/81,169.00 |
| Mkt cap | 179.98M |
| P/E | - |
| Div/yield | - |
| EPS | -0.77 |
| Shares | 35.92M |
| Beta | - |
| Inst. own | 93% |
Events
May 14, 2013
ZELTIQ Aesthetics Inc at Bank of America Merrill Lynch Health Care Conference
Apr 25, 2013
Q1 2013 ZELTIQ Aesthetics Inc Earnings Conference Call
Mar 12, 2013
Q4 2012 ZELTIQ Aesthetics Inc Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -37.44% | -39.56% |
| Operating margin | -37.36% | -39.42% |
| EBITD margin | - | -37.32% |
| Return on average assets | -35.03% | -30.72% |
| Return on average equity | -43.23% | -36.12% |
| Employees | 209 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 100, 4698 Willow Road
PLEASANTON, CA 94588
United States - Map
+1-925-4742500 (Phone)
+1-925-4742599 (Fax)
PLEASANTON, CA 94588
United States - Map
+1-925-4742500 (Phone)
+1-925-4742599 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Zeltiq Aesthetics, Inc. operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. It develops Cryolipolysis, a technology that enables the reduction of fat tissue near nerves, muscle, and bones. The Company develops a non-invasive technology for aesthetic applications and plastic surgery. Its product is used as a skin cooling device to minimize pain and thermal injury during laser and dermatological treatments.
Officers and directors
| Mark J. Foley | President, Chief Executive Officer, Director | |
| Patrick Williams | Chief Financial Officer, Senior Vice President | |
| Michael C. Genau | President - North American Franchise | |
| Sergio Garcia-Rodriguez | Senior Vice President, General Counsel and Corporate Secretary | |
| Richard W. Poinsett | Senior Vice President - Operations | |
| Dennis J. Jarvis Ph.D. | Chief Marketing Officer | |
| Kristine N. Tatsutani Ph.D. | Vice President - Enhanced Clinical Outcomes, Chief Technology Officer | |
| Mary M. Fisher | Director | |
| Jean M. George | Independent Director | |
| Kevin C. O'Boyle | Independent Director |